Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Revelation Biosciences ( (REVB) ).
On September 10, 2025, Revelation Biosciences entered into inducement offer letters with holders of existing warrants to exercise their warrants at $2.20 per share, generating approximately $9.6 million in gross proceeds. This transaction, involving the issuance of new Class I Common Stock Warrants, aims to support the company’s clinical development plans and general corporate purposes, potentially impacting its operational capacity and market positioning.
The most recent analyst rating on (REVB) stock is a Buy with a $60.00 price target. To see the full list of analyst forecasts on Revelation Biosciences stock, see the REVB Stock Forecast page.
Spark’s Take on REVB Stock
According to Spark, TipRanks’ AI Analyst, REVB is a Underperform.
Revelation Biosciences is heavily challenged financially with no revenue and persistent losses. Technical indicators suggest bearish momentum, while valuation metrics reflect severe investor concerns, particularly due to the negative P/E ratio. The company’s reliance on external financing due to negative cash flows adds to the risk profile.
To see Spark’s full report on REVB stock, click here.
More about Revelation Biosciences
Revelation Biosciences, Inc. is a clinical-stage life sciences company focused on rebalancing inflammation using its proprietary formulation Gemini. The company is engaged in multiple programs to evaluate Gemini, including as a prevention for post-surgical infection, prevention for acute kidney injury, and treatment of chronic kidney disease.
Average Trading Volume: 412,421
Technical Sentiment Signal: Sell
Current Market Cap: $3.26M
For an in-depth examination of REVB stock, go to TipRanks’ Overview page.